3-[双-(2-甲氧基羰基乙基)-磷]-丙酸甲酯 | 29269-17-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-[双-(2-甲氧基羰基乙基)-磷]-丙酸甲酯
• 英文名称: trimethyl 3,3',3''-phosphinetriyltripropanoate
• 英文别名: trimethyl 3,3',3''-phosphanetriyltripropionate；Tri(2-methoxycarbonylethyl)phosphine；methyl 3-bis(3-methoxy-3-oxopropyl)phosphanylpropanoate
• CAS: 29269-17-8
• 化学式: C₁₂H₂₁O₆P
• 分子量: 292.269
• InChiKey: GCGYESORUFVNSP-UHFFFAOYSA-N

物化性质

• 沸点：
  365.4±37.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  19
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2915900090

反应信息

• 作为反应物：
  描述：

  3-[双-(2-甲氧基羰基乙基)-磷]-丙酸甲酯 在 lithium aluminium tetrahydride 、 偶氮二甲酸二异丙酯 、 双氧水 、 溶剂黄146 、 三苯基膦 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 7.0h， 生成 S-(3-(bis(3-hydroxypropyl)phosphoryl)propyl) ethanethioate
  参考文献：
  名称：

  [EN] NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE
  [FR] NOUVEAUX AGENTS CYTOTOXIQUES POUR LA CONJUGAISON DE MÉDICAMENTS AVEC LA MOLÉCULE DE LIAISON CELLULAIRE

  摘要：

  提供了细胞毒性药物，吡咯并[2,1-c][1,4]苯二氮杂环己烷（PBD）衍生物，它们与细胞结合剂的结合物，以及在靶向治疗癌症、自身免疫性疾病和传染病中的制备和治疗用途。

  公开号：

  WO2015028850A1
• 作为产物：
  描述：

  甲醇 、 三(2-氰乙基)膦 在 ion-exchange resin + form> 、 水 作用下， 生成 3-[双-(2-甲氧基羰基乙基)-磷]-丙酸甲酯
  参考文献：
  名称：

  Yakovenko,T.V. et al., Journal of general chemistry of the USSR, 1978, vol. 48, p. 1411 - 1413

  摘要：

  DOI：

文献信息

• Disruption of mitochondrial redox homeostasis by enzymatic activation of a trialkylphosphine probe
  作者：Jade Nguyen、Alina Tirla、Pablo Rivera-Fuentes

  DOI：10.1039/d0ob02259d

  日期：——

  Redox homeostasis is essential for cell function and its disruption is associated with multiple pathologies. Redox balance is largely regulated by the relative concentrations of reduced and oxidized glutathione. In eukaryotic cells, this ratio is different in each cell compartment, and disruption of the mitochondrial redox balance has been specifically linked to metabolic diseases. Here, we report

  氧化还原稳态对细胞功能至关重要，其破坏与多种病理相关。氧化还原平衡主要受还原型和氧化型谷胱甘肽的相对浓度调节。在真核细胞中，该比例在每个细胞区室中是不同的，并且线粒体氧化还原平衡的破坏已与代谢性疾病特别相关。在这里，我们报告的探针被内源性硝基还原酶选择性激活，并释放三丁基膦以触发线粒体中的氧化还原应激。机理研究表明，与直觉相反，线粒体中还原剂的释放通过超氧化物的积累迅速诱导了氧化应激。该反应由谷胱甘肽介导，表明还原性和氧化性应激之间存在联系。此外，
• A Chemical Probe for Protein Crotonylation
  作者：Jeffrey Bos、Tom W. Muir

  DOI：10.1021/jacs.7b13141

  日期：2018.4.11

  Protein lysine crotonylation has emerged as an important post-translational modification (PTM) in the regulation of gene transcription through epigenetic mechanisms. Here we introduce a chemical probe, based on a water-soluble phosphine warhead, which reacts with the crotonyl modification. We show that this reagent is complementary to antibody-based tools allowing detection of endogenous cellular proteins

  蛋白质赖氨酸巴豆酰化已成为通过表观遗传机制调控基因转录的重要翻译后修饰 (PTM)。在这里，我们介绍了一种基于水溶性膦弹头的化学探针，它与巴豆酰改性反应。我们表明该试剂与基于抗体的工具互补，可以检测内源性细胞蛋白，例如携带巴豆酰化 PTM 的组蛋白。该工具还用于证明转录共激活因子 p300 的组蛋白酰化活性可以通过正反馈机制通过预先存在的赖氨酸巴豆酰化来激活。该试剂为分析该 PTM 提供了一种通用且灵敏的探针。
• NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE
  申请人：HANGZHOU DAC BIOTECH CO., LTD

  公开号：US20160207949A1

  公开（公告）日：2016-07-21

  The present invention is related to novel cytotoxic agents, pyrrolo[2,1-c][1,4]benzodiazepine (PBD) derivatives, their conjugates with a cell-binding agent, the preparation and the therapeutic uses in the targeted treatment of cancers, autoimmune disorders, and infectious diseases.

  本发明涉及一种新型细胞毒性剂，吡咯并[2,1-c][1,4]苯二氮平（PBD）衍生物，其与细胞结合剂的结合物，以及在靶向治疗癌症，自身免疫性疾病和传染病方面的制备和治疗用途。
• NOVEL MUCOLYTIC AGENTS
  申请人：JOHNSON Michael R.

  公开号：US20150307530A1

  公开（公告）日：2015-10-29

  Provided is a method of liquefying mucus from mucosal surfaces by administering compounds containing a phosphine group.

  提供了一种通过给予含有膦基团化合物的方法，使粘液从黏膜表面液化的方法。
• The role of functionalized phosphines in the hydrogenation of carboxylic acids in the presence of phosphine substituted hydrido ruthenium complexes
  作者：Antonella Salvini、Piero Frediani、Mario Bianchi、Franco Piacenti、Leonardo Pistolesi、Luca Rosi

  DOI：10.1016/s0022-328x(99)00038-8

  日期：1999.6

  Hydride ruthenium carbonyl complexes substituted by functionalized phosphines such as H4Ru4(CO)(8)[P(CH2OCOR)(3)](4) have been synthesized and tested as catalysts in the hydrogenation of carboxylic acids. These complexes are more active than those reported previously, containing trialkyl- or triarylphosphines. On the basis of their behavior, their different activity has been explained in terms of an involvement of the phosphine ligand in the catalytic cycle. The ester group present in the phosphine P(CH2OCOR)(3) is hydrogenated to produce an alcohol (RCH2OH) and a P(CH2OH) group which, in turn, reacts with the free acid present in solution to restore the P(CH2OCOR) group. This hypothesis has been confirmed by the reactivity of the possible intermediate H4Ru4(CO)(8)[P(CH2OH)(3)](4) with acetic acid. Another support to this statement is the almost equal catalytic activity, displayed by H4Ru4(CO)(8)[P(CH2OCOR)(3)](4) complexes, whatever the R group present, in the phosphine ligand, in the hydrogenation of carboxylic acids. These complexes, on the other hand, are less active than the corresponding tributylphosphine substituted ones in the hydrogenation of alkenes and ketones. Finally when the phosphine ligand is P(CH2CH2COOCH3)(3) the ester group is not reduced and consequently the catalytic activity of this complex in the hydrogenation of carboxylic acids is very low. (C) 1999 Elsevier Science S.A. All rights reserved.